Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows
Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase 3 study show. This maintenance therapy was given after partial or complete response to first-line platinum-based chemotherapy. The benefits were, however, even more pronounced in women with mutations in the BRCA genes, and others involved in homologous recombination (HR) DNA repair, these early results show. The results were presented at the European Society for Medical Oncology (ESMO) Congress 2019 that recently took place in Barcelona, Spain. The oral presentation was titled, “Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *